DAL MASO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 917
EU - Europa 198
AS - Asia 52
OC - Oceania 2
Totale 1.169
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 917
IT - Italia 107
SE - Svezia 36
CN - Cina 34
DE - Germania 17
FI - Finlandia 14
GB - Regno Unito 12
IN - India 9
TW - Taiwan 4
PL - Polonia 3
SG - Singapore 3
AU - Australia 2
CH - Svizzera 2
IE - Irlanda 2
NL - Olanda 2
TR - Turchia 2
BE - Belgio 1
ES - Italia 1
UA - Ucraina 1
Totale 1.169
Salva come PNG Salva come JPEG
Città #
Fairfield 179
Chandler 134
Ashburn 67
Woodbridge 56
Cambridge 55
Seattle 52
Houston 50
Padova 41
Ann Arbor 36
Wilmington 32
San Diego 27
Medford 17
Princeton 17
Beijing 13
Des Moines 13
Helsinki 13
New York 13
Roxbury 11
Milan 9
Columbus 8
Pune 8
Ogden 7
London 6
Hsinchu County 4
Arzignano 3
Guangzhou 3
Rome 3
Treviso 3
Turin 3
Washington 3
Amsterdam 2
Belluno 2
Boardman 2
Brisbane 2
Castagnole 2
Dublin 2
Duncan 2
Frankfurt am Main 2
Gdansk 2
Genoa 2
Grisignano di Zocco 2
Jinan 2
Los Angeles 2
Lucca 2
Milazzo 2
Nettuno 2
Pignone 2
Portland 2
Southwark 2
Ankara 1
Arezzo 1
Bari 1
Bellaterra 1
Changsha 1
Chicago 1
Gunzenhausen 1
Hanover 1
Hounslow 1
Jolanda di Savoia 1
Kharkiv 1
Kilburn 1
Lappeenranta 1
Leuven 1
Maida Vale 1
Marostica 1
Munich 1
Nagercoil 1
Nanchang 1
Norwalk 1
Pisa 1
Santa Clara 1
Seregno 1
Shanghai 1
Shenyang 1
Torreglia 1
Vicenza 1
Zonguldak 1
Totale 952
Salva come PNG Salva come JPEG
Nome #
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 118
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 111
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 86
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 76
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 72
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 64
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 64
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 62
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 62
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 60
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 57
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 57
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 55
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors 54
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 52
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 47
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 30
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 19
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 16
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 13
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments 10
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 8
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis 6
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients 5
Totale 1.204
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.994
article - articoli 5.994
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.988
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020136 0 0 15 62 9 4 6 9 10 6 11 4
2020/2021180 9 4 14 2 1 14 36 12 17 15 8 48
2021/2022384 19 43 54 9 26 52 60 9 13 18 25 56
2022/2023270 31 39 15 38 31 21 5 20 53 6 11 0
2023/2024234 21 21 27 28 17 40 18 24 21 13 4 0
Totale 1.204